A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?

NCT ID NCT04691323

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study follows adolescents and young adults (ages 12–21) with sickle cell disease who take hydroxyurea, a medication that helps prevent pain crises and other complications. The researchers are testing whether a mobile app called HU-Go can help these patients build a consistent medication habit and improve their quality of life. Over time, they will track how closely participants stick to their hydroxyurea schedule and measure any changes in pain, daily functioning, and overall well-being. The goal is to understand what helps or hinders medication adherence in this age group, so that better support tools can be developed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HU-Go mobile app designed to support adherence to hydroxyurea medication
What this could lead to
If the app helps young people take hydroxyurea more consistently, it could point toward a simple digital tool to improve quality of life and reduce complications in sickle cell disease.
What could go wrong
This is an early, observational study, so it cannot prove the app causes better adherence or health outcomes. Results may not apply to all patients, and the app's effectiveness depends on real-world usage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE B+ THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ann & Robert H Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.